BSX
Boston Scientific Corp
44.70$
+0.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 19.1% | 18.5% | 22.3% | 24.2% | 23.0% | 17.6% | 18.3% | 17.1% | 18.8% | 20.1% | 19.6% | 17.6% | |
| 2.8% | 2.5% | 6.4% | 7.9% | 6.6% | 1.1% | 1.8% | 1.3% | 3.0% | 4.7% | 3.4% | 1.2% | |
| 2.8% | 2.5% | 6.4% | 7.9% | 6.6% | 1.1% | 1.8% | 1.3% | 3.0% | 4.7% | 3.4% | 1.2% | |
| 6.2% | 6.3% | 6.3% | 6.5% | 6.6% | 6.5% | 6.7% | 6.8% | 6.6% | 6.7% | 6.8% | 6.7% | |
| 7.1% | 7.1% | 7.0% | 7.0% | 7.2% | 7.1% | 7.1% | 6.9% | 6.8% | 6.7% | 7.0% | 7.2% | |
| 9.1% | – | – | – | 9.2% | 9.5% | 9.6% | 9.5% | 10.0% | 10.3% | – | – | |
| 40.0% | 40.9% | 39.2% | 38.8% | 39.5% | 43.4% | 43.2% | 43.5% | 42.6% | 41.9% | 41.8% | 41.2% | |
| 17.2% | 17.1% | 15.9% | 14.6% | 15.1% | 17.0% | 16.4% | 17.5% | 16.8% | 16.1% | 15.9% | 15.3% | |
| 43.8% | 44.4% | 45.0% | 44.5% | 45.0% | 44.1% | 44.1% | 45.5% | 44.7% | 44.0% | 41.1% | 44.3% | |
| 13.5% | 14.0% | 13.4% | 15.0% | 15.5% | 16.2% | 12.6% | 12.5% | 12.5% | 12.5% | 10.3% | 14.2% | |
| 1.5% | 1.5% | 3.0% | 4.3% | 4.3% | 4.5% | 1.9% | 1.2% | 1.1% | 0.9% | 0.1% | 3.8% | |
| 2.7% | 2.7% | 2.5% | 2.4% | 2.4% | 2.4% | 2.5% | 2.3% | 2.3% | 2.6% | 2.6% | 2.7% | |
| 24.6% | 24.4% | 26.0% | 24.2% | 24.2% | 22.4% | 25.9% | 26.4% | 25.7% | 25.5% | 24.5% | 23.9% | |
| 55.5% | 54.9% | 54.3% | 54.9% | 54.4% | 55.3% | 55.3% | 53.9% | 54.8% | 55.5% | 58.3% | 55.1% | |
| 0.9% | 2.3% | 3.6% | 4.4% | 5.5% | 6.8% | 8.3% | 10.0% | 11.5% | 12.8% | 15.6% | 17.3% | |
| 4.3% | 4.2% | 4.0% | 4.0% | 3.9% | 3.8% | 3.7% | 3.6% | 3.5% | 3.4% | 3.4% | 3.3% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.